No items found.
Update

PRESS RELEASE: PathoFinder and EWC Diagnostics partnership to meet COVID-19 testing demands in the Netherlands.

PathoFinder and EWC Diagnostics announce their collaboration to rapidly advance the expansion of COVID-19 testing capacity in the Netherlands by providing the Dutch government with complete sets of sampling materials and SARS-CoV-2 PCR kits.

Within this strategic partnership, EWC provides nasal- and throat swabs and Viral Transport Medium (VTM). PathoFinder produces the RealAccurate® Quadruplex SARS-CoV-2 PCR kit (CE-IVD), which has been validated and approved by the Dutch ational Institute for Public Health and the Environment (RIVM). The PCR kit targets both the N gene and the RdRp gene of the virus, allowing viral detection as well as confirmation of a positive result, in one. EWC Diagnostics coordinates and distributes this unique combination of products to all test locations in the Netherlands.

EWC Diagnostics, based in Steenwijk, the Netherlands, delivers a wide range of products and services to microbiological laboratories in the Benelux. From the start of the COVID-19 pandemic, EWC accelerated their support and distribution of COVID-19 testing materials to Dutch hospitals, and have proven to be a reliable partner for the government.

The molecular diagnostics firm PathoFinder, based in Maastricht in the Netherlands, develops and commercializes multiplex in-vitro diagnostics for infectious diseases. PathoFinder is particularly active in the fields of respiratory tract infections, meningitis and encephalitis, gastro-intestinalinfections and sexually transmitted diseases. PathoFinder have developed and launched four SARS-CoV-2 kits since March 2020 and continue to grow and meet the increased demand for COVID-19 testing.

This outstanding collaboration of Dutch SME’s brings molecular diagnostics expertise together to better meet the vast testing capacity demands created by the SARS-CoV-2 pandemic.

The official press release can be downloaded:

Download